BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30003738)

  • 1. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
    Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females.
    Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Al-Harbi NO; Hassan ZK; Alsheikh A; Al Theyab AI; Aldelemy ML; Sayed-Ahmed MM
    Asian Pac J Cancer Prev; 2015; 16(2):541-9. PubMed ID: 25684485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p16 and pRB in invasive breast cancer.
    Shin E; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
    Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
    [No Abstract]   [Full Text] [Related]  

  • 9. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    Fumagalli C; Pruneri G; Possanzini P; Manzotti M; Barile M; Feroce I; Colleoni M; Bonanni B; Maisonneuve P; Radice P; Viale G; Barberis M
    Breast Cancer Res Treat; 2012 Jul; 134(1):131-7. PubMed ID: 22228432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients.
    Pirouzpanah S; Taleban FA; Mehdipour P; Atri M
    J Mol Med (Berl); 2015 Aug; 93(8):917-34. PubMed ID: 25805039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer.
    Vo LT; Thuan TB; Thu DM; Uyen NQ; Ha NT; To TV
    Asian Pac J Cancer Prev; 2013; 14(12):7713-8. PubMed ID: 24460357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
    Sharma G; Mirza S; Yang YH; Parshad R; Hazrah P; Datta Gupta S; Ralhan R
    Cell Oncol; 2009; 31(6):487-500. PubMed ID: 19940364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
    Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
    BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.